EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSCMIG00000018756
Gene Symbol: MAP2K2
4 Cross references
273 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSCMIG00000019321
Gene Symbol: MAP3K1
4 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSCMIG00000006440
Gene Symbol: MAP3K10
2 Cross references
186 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSCMIG00000017058
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSCMIG00000014500
Gene Symbol: MAP3K13
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSCMIG00000016309
Gene Symbol: MAP3K5
4 Cross references
131 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSCMIG00000005225
Gene Symbol: MAP3K8
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSCMIG00000018511
Gene Symbol: MAP3K9
3 Cross references
195 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSCMIG00000019241
Gene Symbol: MGLL
4 Cross references
209 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSCMIG00000005802
Gene Symbol: MLNR
3 Cross references
172 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSCMIG00000012632
Gene Symbol: NPR2
4 Cross references
260 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSCMIG00000012957
Gene Symbol: NPR3
4 Cross references
211 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).